Freenome, Inc. (PCSC) Form 424B3 — Oct 20, 2026
Freenome (Nasdaq: FRNM) launched SimpleScreen Lung, a blood-based laboratory-developed test, and announced a first-of-its-kind offering that screens for both lung and colorectal cancer via a single blood draw. In an independent cohort of 172 lung cancer cases and 436 controls, SimpleScreen Lung achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value. The companion SimpleScreen CRC test is FDA-approved and, in the 48,000+ participant PREEMPT CRC study, showed 81% CRC sensitivity and 99.9% NPV. The announcement came via an 8-K folded into Prospectus Supplement No.
Key figures
- Crc npv
- 99.9%
- Lung npv
- 99.8%
- Lung cohort
- 172 cases / 436 controls
- Crc sensitivity
- 81%
- Crc specificity
- 90%
- Lung sensitivity
- 85%
- Lung specificity
- 50%
- Preempt crc enrollment
- >48,000 participants
- Shares registered for resale
- 75188742
- Closing price oct 19 2026 usd
- 12.57
- Eligible crc screening not up to date
- up to 60 million people
- Eligible lung screening not up to date
- more than 10 million individuals
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.